Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05407324 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Study acronym: DAZALS
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 1 of 4 entries Enrollment closed, study ongoing · Eligibility criteria expanded, about 15 words · Site details revised at 35 of 35 sites Show 3 more changesShow less
    • Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 15 words
    • Site details revised at 35 of 35 sites
  2. Primary completion pushed from Sep 2026 to Oct 2026 Eligibility criteria expanded, about 92 words · Site details revised at 2 of 35 sites · Study description shortened, about 1 wordv23 Show 3 more changesShow less
    • Eligibility criteria expanded, about 92 words
    • Site details revised at 2 of 35 sites
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Site details revised at 1 of 35 sitesv22
  4. Trial status: Active, Not Recruiting to Recruiting Site details revised at 35 of 35 sitesv21 Show 1 more changeShow less
    • Site details revised at 35 of 35 sites
  5. Primary completion date: Oct 22, 2024 to Sep 2026 Primary endpoints: 2 to 4 · Enrollment target: 249 to 279 · Completion date: May 2027 to Nov 2027 · 5 morev20 Show 8 more changesShow less
    • Primary endpoints: 2 to 4
    • Enrollment target: 249 to 279
    • Completion date: May 2027 to Nov 2027
    • Interventions: Dazucorilant 150 mg (Drug), Dazucorilant 300 mg (Drug), Placebo (Other) to Dazucorilant (Drug), Dazucorilant 150 mg (Drug), Dazucorilant 300 mg (Drug), Placebo (Other)
    • Eligibility criteria expanded, about 220 words
    • Secondary endpoints revised (4)
    • Study description expanded, about 92 words
    • Study arms: 3 to 4

    See this version in full on ClinicalTrials.gov ↗

Show 18 earlier versionsHide 18 earlier versions
  1. Re-verified, no change to tracked fieldsv19
  2. Secondary endpoints: 3 to 4v18 See this version in full on ClinicalTrials.gov ↗
  3. Primary completion date changed from estimate of Oct 2024 to Oct 22, 2024v17
  4. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 228 to confirmed 249 · Site details revised at 35 of 35 sitesv16 Show 2 more changesShow less
    • Enrollment target: estimated 228 to confirmed 249
    • Site details revised at 35 of 35 sites
  5. Primary completion date: May 2027 to Oct 2024 Enrollment target: 198 to 228 · Completion date: Nov 2027 to May 2027 · Eligibility criteria expanded, about 4 words · 1 morev15 Show 4 more changesShow less
    • Enrollment target: 198 to 228
    • Completion date: Nov 2027 to May 2027
    • Eligibility criteria expanded, about 4 words
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  6. Primary completion date: May 2024 to May 2027 Completion date: Nov 2024 to Nov 2027 · Study description revisedv14 Show 2 more changesShow less
    • Completion date: Nov 2024 to Nov 2027
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  7. Study sites: 34 to 35v13
  8. Study sites: 31 to 34v12
  9. Study sites: 27 to 31v11
  10. Study sites: 26 to 27v10
  11. Study sites: 16 to 26v9
  12. Study sites revised (16)v8 See this version in full on ClinicalTrials.gov ↗
  13. Study sites: 14 to 16v7
  14. Study sites: 11 to 14v6
  15. Study sites: 8 to 11v5
  16. Study sites: 3 to 8v4
  17. Study sites: 1 to 3v3
  18. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Sep 2022 to Nov 15, 2022 · Study title shortened, about 1 wordv2 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2022 to Nov 15, 2022
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Corcept Therapeutics
12 trials monitored
See 1 trial at risk
ALS
387 trials monitored
See 18 trials at risk
The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
Trial Details
NCT Number NCT05407324
Lead Sponsor Corcept Therapeutics
Conditions Amyotrophic Lateral Sclerosis
Enrollment 279 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov